Abstract: Objective To investigate the efficacy of anti-angiogenic targeted therapy combined with chemotherapy in the treatment of advanced lung cancer and its effect on carcinoembryonic antigen, liver and kidney function and blood pressure. Methods A total of 78 patients with advanced lung cancer who were treated in Nantong Cancer Hospital were selected as the research objects, and they were divided into control group (n=39) and observation group (n=39) by random number table method from November 2020 to November 2021. The control group received paclitaxel (albumin binding) combined with cisplatin chemotherapy, and the observation group was treated with bevacizumab on the basis of the treatment of the control group. The clinical treatment effect, blood pressure, cyto-keratin 19 fragment antigen 21-1 (CYFRA21-1) level, carbohydrate antigen 125 (CA125) level, serum cancer levels were compared between the two groups Carcinoembryonic antigen (CEA) level, serum alanine aminotransferase (ALT) level, serum creatinine (Scr) level, serum glutamyl transpeptidase (GGT) level and the occurrence of adverse reactions. Results The clinical treatment effect of the two groups of patients was compared, and the observation group was significantly higher than the control group (P<0.05); the systolic blood pressure and diastolic blood pressure index levels were compared between the two groups before treatment, and there was no statistical difference (P>0.05). After systolic blood pressure and diastolic blood pressure index levels, both groups increased, and the observation group was higher than the control group (P<0.05). compared the levels of CYFRA21-1, CA125, and CEA between the two groups after treatment, the two groups were decreased, and the observation group was lower than the control group (P<0.05). There was no statistical difference (P>0.05). Comparing the levels of ALT, Scr, and GGT between the two groups after treatment, the two groups were all higher than before treatment (P<0.05), but the levels of ALT, Scr, and GGT in the two groups after treatment There was no statistical difference between the two groups (P>0.05). There was no statistical difference in the incidence of adverse reactions such as hematological toxicity, myelosuppression, gastrointestinal reactions, and skin reactions between the two groups (P>0.05). Conclusion Anti-angiogenic targeted therapy combined with chemotherapy in the treatment of advanced lung cancer patients can improve the clinical effect, promote the improvement of tumor marker levels, and will not affect liver and kidney function and increase adverse reactions, but it is easy to increase the blood pressure level of patients, and clinical research needs to continue to deepen Research.

Key words: antiangiogenic targeted therapy, chemotherapy, advanced lung cancer, curative effect, carcinoembryonic antigen, liver and kidney function, blood pressure